Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 5, 2007, Pages 665-673

  Aichhorn, Wolfgang ^a,c   Marksteiner, Josef ^b   Walch, Thomas ^b   Zernig, Gerald ^b   Hinterhuber, Hartmann ^b   Stuppaeck, Christoph ^a   Kemmler, Georg ^b  

^a UNIVERSITY OF SALZBURG   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Department of Psychiatry and Psychotherapy ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CITALOPRAM; FLUOXETINE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PALIPERIDONE; PAROXETINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; AGE; ARTICLE; CAUCASIAN; CHILD PSYCHIATRY; CHILDHOOD DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOPHARMACOLOGY; SCHOOL CHILD; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGING; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SEX CHARACTERISTICS; SMOKING; TANDEM MASS SPECTROMETRY; VALPROIC ACID;

EID: 35848934136     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0045     Document Type: Article

References (30)

1. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C: Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 19:395-401, 2005.
2. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G: Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 21:81-85, 2006.
3. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP: Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors. Therapeut Drug Monitoring 21:105-115, 1999.
4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine - Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193, 1999.
5. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394, 2004.
6. Findling RL, McNamara NK: Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. J Clin Psychiatry 65:30-44, 2004.
7. Fleming J, Chetty M: Psychotropic drug interactions with valproate. Clin Neuropharmacol 28:96-101, 2005.
8. Geller B: Psychopharmacology of children and adolescents - Pharmacokinetics and relationships of plasma serum levels to response. Psychopharmacol Bull 27: 401-409, 1991.
9. Gex-Fabry M, Balant-Gorgia AE, Balant LP: Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Therapeut Drug Monitor 25:46-53, 2003.
10. Grothe DR, Calis KA, Jacobsen L, Kumra S, Devane CL, Rapoport JL, Bergstrom RF, Kurtz DL: Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 20:220-225, 2000.
11. Hagg S, Spigset O, Dahlqvist R: Influence of gender and oral contraceptives on CYP2D6 and CY2ZC19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173, 2001.
12. Hayton WL: Maturation and growth of renal function: Dosing renally cleared drugs in children. AAPS Pharmsci 2:art-3, 2000.
13. Laine K, Yasar U, Widen J, Tybring G: A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81, 2003.
14. Lewis R: Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canad J Psychiatry-Revue Canadienne de Psychiatrie 43:596-604, 1998.
15. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J: Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Disposit 21:1134-1141, 1993.
16. Mauri MC, Steinhilber CPC, Marino R, Invernizzi E, Fiorentini A, Cerveri G, Baldi ML, Barale F: Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 20:55-60, 2005.
17. Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, de Vries R, Kaneko S: Significant pharmacokinetic interaction between risperidone and carbamazepine: Its relationship with CYP2D6 genotypes. Psychopharmacology 162:50-54, 2002.
18. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, Jensen PS: Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 44:548-556, 2005.
19. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
20. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ: Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255:261-268, 2005.
21. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
22. Snoeck E, Vanpeer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J: Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122:223-229, 1995.
23. Sonnier M, Cresteil T: Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893-898, 1998.
24. Stevens JR, Kymissis PI, Baker AJL: Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 15:893-900, 2005.
25. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Wilffert B, De Leij LFMH, de Zeeuw RA, Jonkman JHG: CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55:177-184, 1999.
26. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S: Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321, 2002.
27. Theisen FM, Linden A, Geller F, Schafer H, Martin M, Remschmidt H, Hebebrand J: Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatric Res 35:339-345, 2001.
28. Vitiello B, Jensen PS: Medication development and testing in children and adolescents - Current problems, future directions. Arch Gen Psychiatry 54:871-876, 1997.
29. Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W: Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 25:570-574, 2005.
30. World Health Organization: Manual of the International Classification of Diseases (ICD-10). Geneva, 1992.